Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-01
DOI
10.1038/srep22498
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mixed Effects Modeling Using Stochastic Differential Equations: Illustrated by Pharmacokinetic Data of Nicotinic Acid in Obese Zucker Rats
- (2015) Jacob Leander et al. AAPS Journal
- Integrated PK-PD and agent-based modeling in oncology
- (2015) Zhihui Wang et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression
- (2015) Gregory A. Chang et al. Molecular Oncology
- Therapy-induced tumour secretomes promote resistance and tumour progression
- (2015) Anna C. Obenauf et al. NATURE
- Adaptive stress signaling in targeted cancer therapy resistance
- (2015) E Pazarentzos et al. ONCOGENE
- Treatment Analysis in a Cancer Stem Cell Context Using a Tumor Growth Model Based on Cellular Automata
- (2015) Ángel Monteagudo et al. PLoS One
- Computational Modeling of Tumor Response to Drug Release from Vasculature-Bound Nanoparticles
- (2015) Louis T. Curtis et al. PLoS One
- Current Status of Imaging and Emerging Techniques to Evaluate Liver Metastases From Colorectal Carcinoma
- (2014) Dushyant V. Sahani et al. ANNALS OF SURGERY
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- Bridging Population and Tissue Scale Tumor Dynamics: A New Paradigm for Understanding Differences in Tumor Growth and Metastatic Disease
- (2014) Jill Gallaher et al. CANCER RESEARCH
- The paradigm of mutant p53-expressing cancer stem cells and drug resistance
- (2014) Yoav Shetzer et al. CARCINOGENESIS
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
- (2014) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Quantitative Cell-Free Circulating BRAFV600E Mutation Analysis by Use of Droplet Digital PCR in the Follow-up of Patients with Melanoma Being Treated with BRAF Inhibitors
- (2014) M. F. Sanmamed et al. CLINICAL CHEMISTRY
- The risk of developing a second primary cancer in melanoma patients: A comprehensive review of the literature and meta-analysis
- (2014) Saverio Caini et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Evolution of acquired resistance to anti-cancer therapy
- (2014) Jasmine Foo et al. JOURNAL OF THEORETICAL BIOLOGY
- Acquired resistance to TKIs in solid tumours: learning from lung cancer
- (2014) D. Ross Camidge et al. Nature Reviews Clinical Oncology
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- Epigenetic mechanisms of importance for drug treatment
- (2014) Maxim Ivanov et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade
- (2014) Evan J Lipson et al. Journal for ImmunoTherapy of Cancer
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Modeling vascularized bone regeneration within a porous biodegradable CaP scaffold loaded with growth factors
- (2013) Xiaoqiang Sun et al. BIOMATERIALS
- The Dynamics of Signaling as a Pharmacological Target
- (2013) Marcelo Behar et al. CELL
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
- (2013) Sarah-Jane Dawson et al. NEW ENGLAND JOURNAL OF MEDICINE
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Systems Modeling of Anti-apoptotic Pathways in Prostate Cancer: Psychological Stress Triggers a Synergism Pattern Switch in Drug Combination Therapy
- (2013) Xiaoqiang Sun et al. PLoS Computational Biology
- Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients
- (2012) L. Benesova et al. ANALYTICAL BIOCHEMISTRY
- Cytokine combination therapy prediction for bone remodeling in tissue engineering based on the intracellular signaling pathway
- (2012) Xiaoqiang Sun et al. BIOMATERIALS
- Multi-scale agent-based brain cancer modeling and prediction of TKI treatment response: Incorporating EGFR signaling pathway and angiogenesis
- (2012) Xiaoqiang Sun et al. BMC BIOINFORMATICS
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
- (2012) Hiroshi Haeno et al. CELL
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance
- (2012) Roel H. Wilting et al. DRUG RESISTANCE UPDATES
- Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer
- (2012) Jasmine Foo et al. Journal of Thoracic Oncology
- Genetic heterogeneity and cancer drug resistance
- (2012) Nicholas C Turner et al. LANCET ONCOLOGY
- Combinations of BRAF, MEK, and PI3K/mTOR Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations
- (2012) J. G. Greger et al. MOLECULAR CANCER THERAPEUTICS
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- In silico Experimentation of Glioma Microenvironment Development and Anti-tumor Therapy
- (2012) Yu Wu et al. PLoS Computational Biology
- Mathematical Modeling Predicts Synergistic Antitumor Effects of Combining a Macrophage-Based, Hypoxia-Targeted Gene Therapy with Chemotherapy
- (2011) M. R. Owen et al. CANCER RESEARCH
- The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600EInhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
- (2011) Ruixin Liu et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prediction of Drug Response in Breast Cancer Using Integrative Experimental/Computational Modeling
- (2009) H. B. Frieboes et al. CANCER RESEARCH
- The evolution of tumor metastases during clonal expansion
- (2009) Hiroshi Haeno et al. JOURNAL OF THEORETICAL BIOLOGY
- Tumor-Immune Interaction, Surgical Treatment, and Cancer Recurrence in a Mathematical Model of Melanoma
- (2009) Steffen Eikenberry et al. PLoS Computational Biology
- Model structure and control of bone remodeling: A theoretical study
- (2008) Peter Pivonka et al. BONE
- Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
- (2008) Kazuya Taniguchi et al. CANCER SCIENCE
- Cancer Cell Metabolism: Warburg and Beyond
- (2008) Peggy P. Hsu et al. CELL
- Circulating mutant DNA to assess tumor dynamics
- (2008) Frank Diehl et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now